FOLD Stock UPDATES Amicus Therapeutics (FOLD) 5.50 08/21/2014

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Amicus Therapeutics (FOLD) 5.50 $FOLD

SmarTrend Watching for Potential Pullback in Shares of Amicus Therapeutics After 20.35% Gain
Comtex SmarTrend(R) - Wed Aug 20, 4:00PM CDT
Amicus Therapeutics (NASDAQ:FOLD) traded in a range yesterday that spanned from a low of $5.02 to a high of $5.99. Yesterday, the shares gained 20.4%, which took the trading range above the 3-day high of $4.70 on volume of 33.7 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.

Why Amicus Therapeutics (FOLD) Stock Hit a One-Year High Today
at The Street - Wed Aug 20, 9:29AM CDT
Amicus Therapeutics (FOLD) surged to a 52-week high on Wednesday after the company announced its potential Fabry disease treatment drug migalastat met its primary endpoints in a late-stage study.

Why Amicus Therapeutics, Inc. Stock Is Soaring Today
George Budwell, The Motley Fool - Motley Fool - Wed Aug 20, 9:12AM CDT
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. What: Shares of Amicus Therapeutics , a clinical-stage...

Amicus Therapeutics Has Returned 111.6% Since SmarTrend Recommendation (FOLD)
Comtex SmarTrend(R) - Wed Aug 20, 9:10AM CDT
SmarTrend identified an Uptrend for Amicus Therapeutics (NASDAQ:FOLD) on May 30th, 2014 at $2.42. In approximately 3 months, Amicus Therapeutics has returned 111.57% as of today's recent price of $5.12.

Yes, Call it a Comeback: Amicus Fabry Drug Posts Big Study Win
at The Street - Wed Aug 20, 5:01AM CDT
Based on the positive study results, Amicus intends to seek European approval for migalastat early next year.

Amicus Therapeutics Announces Positive Phase 3 Data From Fabry Monotherapy Study 012
GlobeNewswire - Wed Aug 20, 5:00AM CDT
Migalastat Successfully Meets Both Co-Primary Endpoints of Comparability to Enzyme Replacement Therapy (ERT) on Both Key Measures of Kidney Function

Pre-Market Review on Biotech Equities -- Exelixis, Novavax, Achillion Pharma, XOMA, and Amicus Therapeutics
PR Newswire - Wed Aug 13, 7:50AM CDT
On Tuesday, August 12, 2014, the NASDAQ Composite ended at 4,389.25, down 0.27%, the Dow Jones Industrial Average finished the session at 16,560.54, down 0.06% and the S&P 500 closed at 1,933.75, down 0.16%. During the trading session, seven out of ten sectors finished on a lower note. The S&P 500 Health Care Sector Index ended the day 0.14% lower at 699.06, and the index has declined 1.94% in the previous one month. Investor-Edge has initiated coverage on the following equities: Exelixis Inc. (NASDAQ: EXEL), Novavax Inc. (NASDAQ: NVAX), Achillion Pharmaceuticals Inc. (NASDAQ: ACHN), XOMA Corp. (NASDAQ: XOMA), and Amicus Therapeutics Inc. (NASDAQ: FOLD). Free research on these five companies can be accessed at:

Amicus Therapeutics Announces Second Quarter 2014 Financial Results and Corporate Updates
GlobeNewswire - Thu Aug 07, 3:43PM CDT
Results From Second Phase 3 Fabry Monotherapy Study (Study 012) on Track for 3Q14

Why Amicus Therapeutics (FOLD) Might Surprise This Earnings Season - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Aug 06, 7:44AM CDT
Amicus Therapeutics possess a favorable Zacks Rank and a positive Zacks Earnings ESP

Amicus Therapeutics to Announce Second Quarter 2014 Financial Results on August 7, 2014
GlobeNewswire - Thu Jul 31, 3:00PM CDT
Amicus Therapeutics (Nasdaq:FOLD) today announced a conference call and live audio webcast on Thursday, August 7, 2014 at 5:00 p.m. ET to discuss financial results for the second quarter ended June 30, 2014.

Conference Call Schedules, Publication of Study Results, and Public Offer Pricing - Research Reports on Medivation, Keryx, Amicus, AGTC and Clovis
PR Newswire - Wed Jul 30, 7:50AM CDT
Today, Analysts Review released its research reports regarding Medivation, Inc. (NASDAQ: MDVN), Keryx Biopharmaceuticals Inc. (NASDAQ: KERX), Amicus Therapeutics, Inc. (NASDAQ: FOLD), Applied Genetic Technologies Corporation (NASDAQ: AGTC) and Clovis Oncology, Inc. (NASDAQ: CLVS). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/5255-100free.

Amicus (FOLD) Shares March Higher, Can It Continue? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Jul 29, 10:11AM CDT
Amicus (FOLD) Shares March Higher, Can It Continue?

Applied Genetic Technologies Corporation (AGTC) Looks Strong as Stock Surges 15.3% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Jul 28, 7:44AM CDT
Applied Genetic Technologies Corporation (AGTC) was a big mover last session, as the company saw its shares shoot up over 15% on the day.

Agenus Inc. (AGEN) Looks Strong as Stock Surges 11.15% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Jul 25, 7:44AM CDT
Agenus Inc. (AGEN) was a big mover last session, as the company saw its shares shoot up over 11% on the day.

Amicus Therapeutics (FOLD) Jumps: Stock Rises 7.1% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Jul 24, 8:39AM CDT
Amicus Therapeutics, Inc. (FOLD) was a big mover last session, as its shares rose over 7% on the day.

Hot Stock: Amicus Therapeutics, Shares Gain 9.1% (FOLD)
Comtex SmarTrend(R) - Wed Jul 23, 12:43PM CDT
Amicus Therapeutics (NASDAQ:FOLD) is one of today's best performing low-priced stocks, up 9.1% to $4.18 on 1.1x average daily volume. Amicus Therapeutics has traded 2.2 million shares thus far today, vs. average volume of 2.0 million shares per day. The stock has outperformed the Dow (9.1% to the Dow's -0.2%) and outperformed the S&P 500 (9.1% to the S&P's 0.2%) during today's trading.

14 Insanely Important Biotech/Drug Trading Catalysts for the Rest of 2014
at The Street - Thu Jul 10, 10:54AM CDT
Healthcare investors (and traders) have had a lot to work with so far this year, and the next six months promises to be equally action packed.

Pre-market Equity Watch on Biotech Industry -- Research on Halozyme Therapeutics, XOMA, Amicus Therapeutics, and Arena Pharma
PR Newswire - Thu Jul 10, 6:20AM CDT
On Wednesday, July 09, 2014, the NASDAQ Composite ended at 4,419.03, up 0.63%, the Dow Jones Industrial Average advanced 0.47%, to finish the day at 16,985.61, and the S&P 500 closed at 1,972.83, up 0.46%. The gains were broad based as nine out of ten sectors ended the session in positive. The S&P 500 Health Care Sector Index ended the day at 712.05, up 0.38%, with the index also advancing 5.76% in the previous three months. Investor-Edge has initiated coverage on the following equities: Halozyme Therapeutics Inc. (NASDAQ: HALO), XOMA Corp. (NASDAQ: XOMA), Amicus Therapeutics Inc. (NASDAQ: FOLD) and Arena Pharmaceuticals Inc. (NASDAQ: ARNA). Free technical research on HALO, XOMA, FOLD and ARNA can be downloaded upon signing up at:

Amicus Therapeutics Analyst Report; Solid Pipeline and Near-term Catalysts by BrokerBank Securities, Inc.
PR Newswire - Mon Jul 07, 1:55PM CDT
Lysosomal storage disorders are a group of approximately 50 rare inherited metabolic disorders resulting from defects in lysosomal function. These severe, chronic genetic diseases have unmet medical needs, and include Fabry disease, Gaucher disease, Parkinson's disease, Pompe disease, and Tay-Sachs disease. The market for current drug therapies to address these disorders is estimated to exceed $3 billion.

Can the Uptrend Continue for Amicus (FOLD)? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Jul 07, 7:33AM CDT
Can the Uptrend Continue for Amicus (FOLD)?




Scroll down for more posts ▼

Top 10 Most Recent News Articles

Insta360 Tests Holiday Demand With $170 Gear Discounts

Updated Category News Views 57

A discount banner can reveal plenty about a hardware brand's priorities, and Insta360's latest Black Friday push is plainly built to put more of its ecosystem into customers' hands. The company is advertising savings of up to US$170 across cameras, gimbals, microphones, webcams, and accessories, with the promotion available for a limited time through its own store and...

Continue Reading
GE Aerospace Backs Service Members With $100K Gift

Updated Category News Views 65

A six-figure commitment can look tiny beside jet-engine budgets, yet it can matter a great deal when it reaches people navigating the awkward jump from military service into civilian life. GE Aerospace has committed $100,000 to Embry-Riddle Aeronautical University to support transitioning service members. That is the whole heart of this announcement, and frankly, it is...

Continue Reading
Travelzoo Turns Thanksgiving Delays Into Member Value

Updated Category News Views 108

Airport gridlock is a miserable place to make a membership pitch, yet Travelzoo has found a pretty shrewd angle for it. On November 18, the company said nearly 20 million travelers will move through airports during the upcoming Thanksgiving holiday, when cancellations and delays can turn an ordinary trip into a long, fluorescent-lit slog. Its offer: qualifying Club...

Continue Reading
CATL Makes Its APEC Case Beyond the Electric Car Market

Updated Category News Views 135

A 99-Second Pitch With Bigger Ambitions Battery swapping got a rare moment in the geopolitical sunlight at Shenzhen's APEC CEO Summit, and CATL was plainly trying to make that moment count. Dr. Robin Zeng, the company's founder, chairman and chief executive, used the opening business dialogue to argue that the Asia-Pacific region holds more opportunity than trouble. Fair...

Continue Reading
Frontline Claims Survey Tests AI's Real Desk Impact

Updated Category News Views 113

Claims software can look brilliant in a conference-room demo and still create a fresh pile of headaches for the person handling a real injured worker’s file. That is why the 2026 Workers’ Compensation Benchmarking Study opening its survey to frontline claims professionals matters more than the usual industry questionnaire. This is an operating-reality check, not just...

Continue Reading
Misunderstood Brands Bets Small Cans Can Scale Growth

Updated Category News Views 190

A tiny cocktail can is a brutal little test of whether a spirits brand has legs. Misunderstood Brands is putting four 100mL offerings on the shelf just as its Wegmans distribution expands across the East Coast, and that combination matters more than another glossy flavor announcement. The company is trying to turn products people discovered in bars and restaurants into...

Continue Reading
Linkind's Best Buy Push Tests Smart Outdoor Demand

Updated Category News Views 199

Holiday lights have quietly become a year-round hardware category, and Linkind wants a louder seat at the table. The smart-lighting brand says three outdoor products have been in Best Buy stores across the United States since October 17, 2026: permanent exterior lights, decorative string lights, and solar pathway lights. That is a real distribution step, not some grand...

Continue Reading
iFLYTEK’s AINOTE Discounts Put E-Ink Utility on Trial

Updated Category News Views 75

A slim E-Ink notebook is getting shoved into the Black Friday brawl, and iFLYTEK is betting that less screen glare and more follow-through can still command a serious price. The company has put discounts of up to 25% on its AINOTE lineup, a sensible move in a gadget season where buyers have no shortage of tablets, voice apps, and half-used productivity subscriptions...

Continue Reading
Luxor Targets Device Chaos With Kwik IQ Hub Lockers

Updated Category News Views 86

A dead scanner at shift change can make an expensive digital rollout look downright foolish. Luxor Workspaces is aiming squarely at that unglamorous mess with its newly available Kwik IQ Hub smart-locker collection, introduced at the Connected Worker: Manufacturing Summit in Chicago on October 13–15. The pitch is not flashy: put shared radios, scanners, headsets,...

Continue Reading
Resolve Adds Cahaba in Birmingham Pain-Care Expansion

Updated Category News Views 198

Pain-care consolidation has a peculiar way of looking tidy in a release and messy in the real world. Resolve Pain Solutions announced on November 18, 2026, that it has acquired Cahaba Pain and Spine Care, an established provider serving greater Birmingham, Alabama. On its face, this is a straightforward expansion move: buy a respected local practice, retain its physician...

Continue Reading

Top 5 Most Recently Viewed Articles

Insightful Update on Scully Royalty's Annual Meeting Plans

Updated Category News Views 129

Insightful Overview of Scully Royalty's Annual Meeting Scully Royalty Ltd. (NYSE: SRL) has recently provided valuable insights regarding its upcoming annual general meeting (AGM) scheduled for December 27, 2025. This update follows a noteworthy event involving MILFAM LLC, which filed a purported dissident proxy circular aimed at nominating five candidates for the...

Continue Reading
How a $1,000 Bitcoin Investment Shaped Financial Perspectives

Updated Category News Views 353

The Shift in Bitcoin's Investment Landscape Cryptocurrency has turned into a financial wild west, where fortunes are made and lost at lightning speed. At the center of this universe is Bitcoin, once brushed off by many traditional financiers. One such critic was Jamie Dimon, CEO of JPMorgan & Chase, who didn't hold back his disdain for the digital currency. Dimon’s...

Continue Reading
Netcompany's Share Buyback Program Progress Report

Updated Category News Views 162

Overview of Netcompany's Share Buyback Program In a strategic move to optimize its capital structure, Netcompany Group A/S has initiated a significant share buyback program aiming to repurchase up to DKK 250 million worth of shares. This action is accompanied by a target to acquire a maximum of 1,300,000 shares, reflecting Netcompany's commitment to fulfilling its...

Continue Reading
Ramaco Resources Partners with Goldman Sachs for Minerals Initiative

Updated Category News Views 133

Collaboration with Goldman Sachs Ramaco Resources, Inc. (NASDAQ: METC, METCB) has taken a significant step forward by teaming up with Goldman Sachs & Co. LLC. This partnership aims to establish a new initiative focused on creating a Strategic Critical Minerals Terminal (SCMT) at Ramaco's Brook Mine facility. Strategic Importance of the SCMT The SCMT initiative, approved...

Continue Reading
Understanding V2X's Upgrade to Buy: Key Insights Revealed

Updated Category News Views 96

Understanding V2X's Current Market Position V2X VVX has recently caught the eye of investors after being upgraded to a "Buy" rating. This upgrade marks a significant shift in earnings estimates, which are pivotal in determining stock valuations. The improved earnings outlook reflects a growing sense of optimism among analysts, boosting the overall attractiveness of the...

Continue Reading